influenza
b
virus
caus
seriou
medic
problem
social
disrupt
everi
year
particular
countri
world
viru
notori
fickl
may
attack
citizen
say
two
adjac
countri
third
rare
global
pandem
viru
emerg
caus
million
death
worldwid
sar
outbreak
illumin
weak
plan
sudden
outbreak
diseas
modern
societi
particular
panic
grip
caus
intens
econom
disrupt
mani
commun
world
neither
prepar
global
pandem
acut
epidem
influenza
neuraminidas
inhibit
although
mutant
occur
mutant
compromis
less
virul
drugsensit
parent
spread
less
easili
two
drug
could
stockpil
prepar
influenza
pandem
importantli
clinic
scientif
experi
need
gain
use
inhibitor
yearli
conflagr
epidem
influenza
uncheck
great
harm
commun
recent
truli
global
respiratori
viru
influenza
caus
huge
medic
econom
problem
involv
ten
million
person
pandem
year
well
interven
season
complet
new
human
pathogen
sar
coronaviru
join
influenza
global
respiratori
viru
recent
outbreak
south
east
asia
hong
kong
although
minut
comparison
influenza
least
teach
us
modern
societi
react
brand
new
viral
infect
compar
term
sar
outbreak
restrict
number
patient
infect
mortal
hand
influenza
spread
slowli
first
origin
armi
camp
winter
therefor
reserv
judgement
futur
spread
sar
unexpectedli
air
travel
transport
sarsinfect
person
least
countri
small
outbreak
describ
unpreced
decis
recommend
restrict
travel
entri
hong
kong
china
canada
attempt
contain
outbreak
viru
new
like
pandem
influenza
may
emerg
avian
anim
sourc
possibl
civet
cat
sinc
antivir
drug
vaccin
coronaviru
commun
resort
use
face
mask
rel
small
intervent
reduc
live
densiti
care
wash
cup
saucer
famili
environ
could
reduc
transmiss
viru
like
sar
highli
contagi
viru
like
influenza
main
lesson
sar
outbreak
next
influenza
global
pandem
viru
aris
virtual
unlimit
demand
antivir
drug
vaccin
everi
commun
world
place
entir
relianc
two
class
antiinfluenza
drug
blocker
amantadin
rimantadin
antineuraminidas
drug
neuraminidas
inhibitor
nai
comparison
sar
mind
whole
commun
se
asia
edg
panic
would
medic
commun
abl
cope
truli
global
pandem
influenza
prepar
could
situat
descend
chao
even
anarchi
extent
social
polit
question
scientif
discoveri
practic
applic
case
involv
antiinfluenza
drug
key
prevent
problem
first
place
one
first
antivir
drug
discov
amantadin
inhibit
influenza
b
viru
earli
observ
extrem
specif
antivir
set
scientif
scene
subsequ
drug
virus
two
broadspectrum
antivir
describ
ribavirin
cidofovir
influenza
caus
seriou
respiratori
infect
widespread
outbreak
influenza
b
influenza
b
viru
like
influenza
still
caus
pneumonia
death
soon
discoveri
amantadin
child
social
medic
repercuss
influenza
pandem
small
group
chemist
vienna
devis
synthes
inhibitor
viral
enzym
neuraminidas
na
class
enzym
widespread
bacteri
viral
mammalian
world
speci
particular
enzym
basic
na
cleav
sialic
acid
usual
termin
posit
sugar
side
chain
glycoprotein
given
biochem
structur
differ
class
na
seem
imposs
dream
select
inhibitor
viral
na
could
found
first
drug
fana
acetyl
neuramin
acid
profound
block
effect
influenza
na
less
inhibitori
effect
bacteri
mammalian
na
drug
vivo
activ
mice
infect
influenza
two
decad
later
arm
xray
crystallographi
data
influenza
na
group
medic
chemist
studi
detail
interact
fanalik
na
inhibitor
atom
level
perceiv
interact
sialic
acid
lookalik
molecul
fana
amino
acid
activ
site
na
could
improv
ad
side
chain
fana
thu
origin
inhibitor
redesign
ad
guanidinyl
group
replac
hydroxyl
carbon
atom
drug
zanamivir
test
laboratori
scientif
group
realiz
made
major
discoveri
first
announc
occupi
front
page
natur
magazin
zanamivir
power
inhibitor
complet
rang
influenza
b
virus
includ
pandem
virus
even
recent
isol
virus
chicken
futur
could
becom
pandem
excitingli
drug
given
aerosol
spray
signific
viru
block
effect
prevent
death
influenza
pneumonia
mice
ferret
model
human
use
drug
inhal
develop
soon
appar
new
drug
could
stop
viru
spread
infect
person
commun
household
socal
postinfect
prophylact
mode
even
person
alreadi
show
clinic
symptom
influenza
drug
quickli
abl
resolv
clinic
present
influenza
reduc
temperatur
abrog
cough
reduc
viru
load
therapeut
mode
present
virolog
breakthrough
decad
surprisingli
sever
scientif
group
around
world
work
improv
first
member
new
class
na
inhibitor
second
breakthrough
came
anoth
biotech
compani
identifi
inhibitori
molecul
lipophil
side
chain
drug
could
taken
oral
call
oseltamivir
headtohead
comparison
two
nai
molecul
attempt
clinic
would
surpris
signific
differ
efficaci
power
drug
influenza
b
laboratori
anim
model
separ
review
analys
five
placebocontrol
prophylact
studi
zanamivir
oseltamivir
carri
mainli
usa
europ
overal
protect
effect
drug
vari
suggest
clearli
drug
use
effect
commun
prevent
spread
infect
less
evid
use
vulner
set
home
elderli
attack
rate
high
everi
reason
suggest
new
inhibitor
effect
prevent
diseas
random
doubleblind
placebocontrol
postinfect
prophylact
studi
conduct
centr
north
america
europ
winter
worthi
detail
analysi
studi
includ
three
hundr
seventyseven
index
case
ic
influenza
laboratoryconfirm
influenza
infect
household
contact
age
year
ic
includ
contact
influenzaposit
ic
household
contact
randomli
assign
household
cluster
take
mg
oseltamivir
n
placebo
n
daili
day
within
h
symptom
onset
ic
ic
influenza
receiv
antivir
treatment
clinic
influenza
contact
influenzaposit
ic
confirm
detect
viru
shed
nose
throat
swab
fourfold
greater
increas
influenzaspecif
serum
antibodi
titr
baselin
convalesc
serum
sampl
contact
influenzaposit
ic
overal
protect
efficaci
oseltamivir
clinic
influenza
individu
household
contact
ic
oseltamivir
also
significantli
reduc
incid
clinic
influenza
protect
efficaci
viral
shed
inhibit
contact
take
oseltamivir
protect
efficaci
viru
isol
oseltamivir
recipi
retain
sensit
activ
metabolit
oseltamivir
well
toler
gastrointestin
tract
effect
report
similar
frequenc
oseltamivir
placebo
recipi
similar
data
report
use
zanamivir
prophylact
studi
campu
commun
regard
therapi
use
drug
abrog
symptom
clinic
studi
commun
show
administr
inhal
zanamivir
within
h
natur
influenza
b
infect
significantli
reduc
durat
symptomat
ill
day
versu
day
compar
placebo
importantli
data
also
indic
zanamivir
treatment
reduc
impact
influenza
viru
infect
patient
product
health
statu
number
contact
made
healthcar
profession
compar
studi
oseltamivir
commun
total
healthi
unimmun
adult
age
year
enrol
present
within
h
onset
temperatur
plu
least
one
respiratori
symptom
one
constitut
symptom
individu
random
one
three
treatment
group
oseltamivir
mg
twice
daili
oseltamivir
mg
twice
daili
day
placebo
total
particip
confirm
influenza
durat
ill
initi
therapi
reduc
approxim
oseltamivir
group
mg
twice
daili
group
median
durat
ill
reduc
day
compar
day
placebo
group
p
mg
twice
daili
group
durat
reduc
day
p
also
signific
decreas
symptom
ill
volunt
treat
oseltamivir
report
rapid
return
normal
health
usual
activ
addit
incid
secondari
complic
predefin
pneumonia
bronchiti
sinus
otiti
media
subject
influenza
reduc
placebo
recipi
two
oseltamivirtr
group
antibiot
prescript
complic
reduc
whitley
et
al
describ
random
doubleblind
placebo
studi
children
year
age
clinic
diagnos
influenza
fever
histori
cough
coryza
h
durat
children
receiv
mgkg
oseltamivir
placebo
twice
daili
day
six
hundr
ninetyf
children
enrol
serolog
proven
influenza
children
treat
oseltamivir
median
durat
ill
reduc
h
compar
placebo
new
diagnosi
otiti
media
reduc
incid
prescrib
antibiot
significantli
reduc
drug
group
excess
emesi
drug
group
oseltamivir
therefor
appear
efficaci
welltoler
therapi
use
children
within
h
onset
influenza
symptom
impact
studi
report
aoki
et
al
design
investig
relationship
timetotreat
ill
durat
efficaci
paramet
confirm
greater
increment
benefit
gain
treat
influenza
soon
possibl
appear
symptom
total
patient
year
present
within
h
onset
influenza
symptom
treat
oseltamivir
mg
twice
day
day
influenza
season
laboratoryconfirm
influenza
viru
infect
earlier
intervent
associ
shorter
ill
durat
p
initi
therapi
within
first
h
fever
onset
reduc
total
median
ill
durat
h
day
intervent
h
intermedi
intervent
reduc
ill
proportion
compar
h
addit
earlier
administr
oseltamivir
reduc
durat
fever
sever
symptom
time
return
baselin
activ
health
score
oseltamivir
well
toler
common
advers
event
nausea
vomit
transient
gener
occur
first
dose
influenza
ill
associ
viru
replic
respiratori
tract
peak
h
ill
onset
thu
drug
like
oseltamivir
zanamivir
would
amelior
ill
sole
inhibit
viru
replic
must
administ
first
h
ill
prefer
earli
possibl
earli
intervent
shown
strongli
associ
shorter
durat
reduc
sever
ill
faster
resolut
fever
faster
return
normal
health
activ
primari
endpoint
data
demonstr
total
durat
ill
could
halv
influenza
patient
treat
earli
compar
intervent
h
data
complement
result
earlier
studi
oseltamivir
subject
start
activ
treatment
within
h
symptom
onset
durat
compar
initi
therapi
within
h
onset
ill
unlik
measl
previou
time
smallpox
influenza
diagnos
certainti
clinician
rather
clinic
hit
rate
around
mani
virus
includ
recent
discov
sar
coronaviru
paramyxovirus
adenoviru
respiratori
syncyti
viru
caus
fever
cough
ach
pain
medic
problem
solv
scientif
develop
highspe
min
bedsid
test
influenza
unexpectedli
new
drug
came
modern
immens
solid
barriermed
econom
govern
mani
countri
face
medic
scientif
advanc
across
wide
rang
diseas
alarm
question
increasingli
ask
sole
new
drug
bring
solac
relief
patient
alongsid
save
money
basi
approach
least
influenza
younger
person
unless
diabet
asthma
recov
influenza
without
medic
intervent
contrast
grandpar
young
babi
much
like
end
accid
emerg
clinic
chest
pain
breathless
need
rapid
medic
attent
virusinduc
bronchiti
bronchopneumonia
new
econom
focu
whether
give
nai
drug
inde
older
blocker
rimantadin
amantadin
hospit
visit
avert
therebi
avoid
cost
cost
save
would
justifi
expenditur
drug
essenc
scenario
enquir
much
drug
need
use
prevent
one
person
come
hospit
cost
figur
look
gloomi
organ
usual
attempt
restrict
widespread
use
new
drug
econom
consider
much
imped
widespread
use
two
class
influenza
inhibitor
europ
wide
use
japan
usa
australia
practic
problem
also
make
sure
drug
wast
noninfluenza
respiratori
diseas
unlik
case
acut
influenza
outbreak
could
occur
interven
year
influenza
reach
epidem
level
yet
circul
commun
even
harder
diagnos
clinic
problem
rather
manageri
medic
scientif
arrang
prescript
use
new
drug
within
h
onset
clinic
symptom
modern
mobil
societi
text
messag
mobil
phone
internet
sure
possibl
arrang
nurs
prescrib
appoint
especi
whilst
influenza
outbreak
progress
influenza
outbreak
last
week
thereaft
practic
soon
return
normal
realiti
use
drug
gener
practic
would
expect
reduc
number
patient
staff
influenza
therefor
help
effici
run
clinic
winter
influenza
crisi
idea
often
rais
context
influenza
lock
away
new
antina
drug
next
pandem
idea
serious
flaw
stock
inhibitor
need
idea
complet
obscur
develop
rational
viru
resist
gene
flaw
practic
antiinfluenza
chemotherapi
event
next
pandem
given
huge
intern
social
disrupt
wit
miniscul
sar
outbreak
experienc
cohort
hospit
gener
practic
doctor
absolut
essenti
prevent
mass
nation
intern
panic
experi
key
word
doctor
nurs
clinic
experi
treat
patient
drug
use
protect
vulner
patient
pandem
plan
could
quickli
twist
chao
wors
regard
drug
resist
mutat
confer
resist
detect
rare
date
drugresist
virus
shown
less
virul
spread
less
easili
anim
model
infect
therefor
noth
replac
care
yearbyyear
use
monitor
new
antiinfluenza
drug
simultan
give
confid
doctor
patient
alik
firstli
influenza
like
common
cold
viru
develop
seriou
infect
spread
rapidli
famili
workplac
confid
diagnos
famili
physician
importantli
new
famili
power
drug
actual
protect
infect
unlik
given
current
low
usag
two
licens
antina
drug
pharmaceut
compani
invest
develop
anoth
molecul
class
analysi
perspect
could
chang
event
seri
major
epidem
cours
truli
global
outbreak
influenza
sar
outbreak
may
harbing
futur
new
respiratori
virus
emerg
bird
anim
viru
famili
includ
coronaviru
therefor
futur
antivir
chemotherapist
may
need
search
widespectrum
antivir
molecul
present
antivir
except
ribavirin
cidofovir
block
replic
narrow
rang
virus
target
virusspecif
protein
enzym
thu
aciclovir
inhibit
herp
virus
dideoxi
nucleosid
analogu
proteas
inhibitor
target
hiv
whilst
oseltamivir
zanamivir
inhibit
influenza
b
virus
influenza
known
perturb
function
rang
gene
infect
cell
mani
success
therapi
exclud
world
infect
target
cellular
protein
therefor
conceptu
new
gener
antivir
could
target
cellular
protein
exampl
protein
cell
enzym
whose
activ
increas
viru
infect
futur
challeng
identifi
gene
gene
product
enhanc
infect
wide
varieti
respiratori
virus
use
cellular
protein
target
new
gener
broad
spectrum
viru
inhibitori
molecul
immedi
press
concern
use
nai
commun
world
allevi
clinic
threat
influenza
elderli
younger
vulner
companion
famili
show
outdat
attitud
centuri
last
influenza
pneumonia
old
man
friend
accept
medic
scientif
commun
